+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

New Drug Development for Known and Emerging Viruses. Edition No. 1. Methods and Principles in Medicinal Chemistry

  • ID: 5185294
  • Book
  • April 2021
  • 448 Pages
  • John Wiley and Sons Ltd
Discusses how to address the need for fighting Ebola, Zika, and other human viruses by building on the successes in antiviral therapy of the past decade 

Written by leading medicinal chemists from academia and industry, this book discusses the entire field of antiviral drug discovery and development from a medicinal chemistry perspective, focusing on antiviral drugs, targets, and viral disease mechanisms. It provides an outlook on emerging pathogens such as Ebola, Zika, West Nile, Lassa, and Norovirus, and includes a chapter on the current Coronoavirus pandemic.  

New Developments in Antiviral Drugs describes the discovery and development process for different classes of viruses and targets based on the experiences from the nine human viruses for which approved drugs are on the market (HIV, HCV, Influenza, RSV, HBV, HPV, HCMV, HSV, and VZV). It covers the properties and development potential of 20 classes of currently approved antivirals, including combination drugs, and looks at novel antiviral strategies against emerging viruses. 

Covers the entire field of antiviral drug discovery and development   Addresses the need for antiviral drugs to combat major health threats such as Ebola, Zika, West Nile, and COVID-19   Summarizes the successes of the past 15 years in developing ground-breaking medicines against 9 major human viruses, both from the medicinal chemistry and the pharmacological angle  Discusses practical and strategic challenges in the drug discovery and development process, including screening technologies, latency, and toxicity issues 

New Developments in Antiviral Drugs is an important book for medicinal chemists, pharmaceutical chemists, virologists, and epidemiologists, and will be of great interest to those in the pharmaceutical industry and public health agencies.
Note: Product cover images may vary from those shown
Human Immunodeficiency Virus (HIV): Targets for therapy and open issues
Human Immunodeficiency Virus (HIV): Anti-HIV drug discovery and development
Hepatitis C Virus (HCV): Curing chronic HCV infections
Influenza Virus: Targets and drugs
Respiratory Syncytial Virus (RSV): Enzymology, antiviral targets, and drugs in development
Hepatitis B Virus (HBV): Development of therapeutic vaccines
Hepatitis B Virus (HBV): Drug targets
Hepatitis B Virus (HBV): Medicinal chemistry of capsid inhibitors
Hepatitis B Virus (HBV): Immunomodulators (Replicor and AIC 649)
Human Cytomegalovirus (HCMV): HMCV polymerase as drug target
Human Cytomegalovirus (HCMV): Inhibitors of HMCV terminase
Herpes Simplex Virus (HSV): Targets and inhibitors
Adeno Viruses
dsDNA Viruses: Antiviral strategies for EBV, human polyoma virus and human herpesvirus 6
ssDNA Viruses: Antiviral strategies for parvovirus B19
Negative-sense ssRNA viruses: Antiviral strategies for Ebola, Marburg, Hendra, Nipah, Lassa, Junin and Machupo viruses
Positive-sense ssRNA viruses: Antiviral strategies
Note: Product cover images may vary from those shown
Helga Rübsamen-Schaeff
Helmut Buschmann Aachen, Germany.
Note: Product cover images may vary from those shown
Adroll
adroll